Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology&reg;

Sarcomas

Supportive Care

Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.

Durvalumab Plus Vaccine Therapy Elicits &lsquo;Encouraging&rsquo; DFS in BCG-Unresponsive NMIBC

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Iparomlimab/Tuvonralimab Plus Chemo &plusmn; Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti&ndash;PD-(L)1 Therapy

Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network&reg;

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Articles

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.

Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer

Findings will help identify patients with breast, ovarian, pancreatic, or prostate cancer who may benefit from targeted therapies.

Researchers Resolve Uncertainty in BRCA2 Testing, Improving Cancer Risk Assessment and Patient Care

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports&mdash;including the New Jersey Devils and the NHL from 2016 to 2021&mdash;for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.

Continuous Synthetic Hypericin Generates Responses in Early-Stage Cutaneous T-Cell Lymphoma

Savolitinib has received full NMPA approval for locally advanced/metastatic non&ndash;small cell lung cancer with MET exon 14 skipping alterations.

Savolitinib Earns Full Approval in China for Locally Advanced/Metastatic MET Exon 14+ NSCLC 

The publication section includes exclusive articles from OncologyLive, highlighting clinical oncology news and insights in cancer care. Read more at OncLive.

Publications | Clinical Oncology News & Insights | OncLive

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

Onclive&reg; Publications

Contemporary Radiation Oncology

Oncology & Biotech News

Oncology Fellows

Special Issues

OncologyLive&reg; is the flagship publication of OncLive&reg;. Each issue delivers expert insights and clinical oncology news and updates, which impact the day-to-day clinical practice of oncology professionals who work tirelessly to help improve patient outcomes.

Oncology Live&reg;

Supplements and Featured Publications

Onclive® Publications

Legacy

Latest Conference Coverage